Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study.

Kim ES, Kelly K, Paz-Ares LG, Garrido P, Jalal S, Mahadevan D, Gutierrez M, Provencio M, Schaefer E, Shaheen M, Johnston EL, Turner PK, Kambhampati SRP, Beckmann R, Hossain A, John WJ, Goldman JW.

Clin Cancer Res. 2018 Aug 6. doi: 10.1158/1078-0432.CCR-18-0651. [Epub ahead of print]

PMID:
30082474
2.

A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.

Tate SC, Sykes AK, Kulanthaivel P, Chan EM, Turner PK, Cronier DM.

Clin Pharmacokinet. 2018 Mar;57(3):335-344. doi: 10.1007/s40262-017-0559-8.

3.

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.

Rosen LS, Goldman JW, Algazi AP, Turner PK, Moser B, Hu T, Wang XA, Tuttle J, Wacheck V, Wooldridge JE, Banck M.

Clin Cancer Res. 2017 Apr 15;23(8):1910-1919. doi: 10.1158/1078-0432.CCR-16-1418. Epub 2016 Oct 10.

4.

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.

Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, Kitano S, Ogasawara K, Turner PK, Mori J, Asou H, Chan EM, Yamamoto N.

Cancer Chemother Pharmacol. 2016 Aug;78(2):281-8. doi: 10.1007/s00280-016-3085-8. Epub 2016 Jun 16.

PMID:
27312735
5.

Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.

Coutant DE, Kulanthaivel P, Turner PK, Bell RL, Baldwin J, Wijayawardana SR, Pitou C, Hall SD.

Clin Pharmacol Ther. 2015 Jul;98(1):76-86. doi: 10.1002/cpt.128. Epub 2015 May 19. Review.

PMID:
25808023
6.

An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.

Jotte RM, Von Hoff DD, Braiteh F, Becerra CR, Richards DA, Smith DA, Garbo L, Stephenson J, Conkling PR, Robert-Vizcarrondo F, Chen J, Turner PK, Chow KH, Tai DF, Ilaria R Jr.

Invest New Drugs. 2015 Feb;33(1):148-58. doi: 10.1007/s10637-014-0160-z. Epub 2014 Sep 28.

PMID:
25260842
7.

A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.

Hamid O, Ilaria R Jr, Garbe C, Wolter P, Maio M, Hutson TE, Arance A, Lorigan P, Lee J, Hauschild A, Mohr P, Hahka-Kemppinen M, Kaiser C, Turner PK, Conti I, Grob JJ.

Cancer. 2014 Jul 1;120(13):2016-24. doi: 10.1002/cncr.28635. Epub 2014 Mar 26.

8.

An exploratory examination of the meanings of residual injuries from intimate partner violence.

Weaver TL, Turner PK, Schwarze N, Thayer CA, Carter-Sand S.

Women Health. 2007;45(3):85-102.

PMID:
18032164
9.

Physiological and reproductive effects of beta adrenergic receptor antagonists in Daphnia magna.

Dzialowski EM, Turner PK, Brooks BW.

Arch Environ Contam Toxicol. 2006 May;50(4):503-10. Epub 2006 Mar 31.

PMID:
16583257
10.

Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children.

Turner PK, Iacono LC, Panetta JC, Santana VM, Daw NC, Gajjar A, Stewart CF.

Cancer Chemother Pharmacol. 2006 Apr;57(4):475-82. Epub 2005 Jul 27.

PMID:
16047146
11.

Increased toxicity to Ceriodaphnia dubia in mixtures of atrazine and diazinon at environmentally realistic concentrations.

Banks KE, Turner PK, Wood SH, Matthews C.

Ecotoxicol Environ Saf. 2005 Jan;60(1):28-36.

PMID:
15482837
12.

Topoisomerase I interactive agents.

Turner PK, Iacono LC, Stewart CF.

Cancer Chemother Biol Response Modif. 2003;21:69-101. Review.

PMID:
15338741
13.

Mainstreaming alternative medicine: doing midwifery at the intersection.

Turner PK.

Qual Health Res. 2004 May;14(5):644-62.

PMID:
15107168
14.

Laboratory and field responses to cadmium: an experimental study in effluent-dominated stream mesocosms.

Brooks BW, Stanley JK, White JC, Turner PK, Wu KB, La Point TW.

Environ Toxicol Chem. 2004 Apr;23(4):1057-64.

PMID:
15095905
15.

Temporal and spatial variability in the estrogenicity of a municipal wastewater effluent.

Hemming JM, Allen HJ, Thuesen KA, Turner PK, Waller WT, Lazorchak JM, Lattier D, Chow M, Denslow N, Venables B.

Ecotoxicol Environ Saf. 2004 Mar;57(3):303-10.

PMID:
15041253
16.

Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer.

Turner PK, Houghton JA, Petak I, Tillman DM, Douglas L, Schwartzberg L, Billups CA, Panetta JC, Stewart CF.

Cancer Chemother Pharmacol. 2004 Mar;53(3):253-60. Epub 2003 Nov 28.

PMID:
14648016
17.

Waterborne and sediment toxicity of fluoxetine to select organisms.

Brooks BW, Turner PK, Stanley JK, Weston JJ, Glidewell EA, Foran CM, Slattery M, La Point TW, Huggett DB.

Chemosphere. 2003 Jul;52(1):135-42.

PMID:
12729696
18.

Topoisomerase I interactive agents.

Kirstein MN, Turner PK, Stewart CF.

Cancer Chemother Biol Response Modif. 2002;20:99-123. Review.

PMID:
12703202
19.

Aquatic ecotoxicology of fluoxetine.

Brooks BW, Foran CM, Richards SM, Weston J, Turner PK, Stanley JK, Solomon KR, Slattery M, La Point TW.

Toxicol Lett. 2003 May 15;142(3):169-83. Review.

PMID:
12691711
20.

Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.

Schwartzberg LS, Petak I, Stewart C, Turner PK, Ashley J, Tillman DM, Douglas L, Tan M, Billups C, Mihalik R, Weir A, Tauer K, Shope S, Houghton JA.

Clin Cancer Res. 2002 Aug;8(8):2488-98.

21.

Holding hands: the immeasurable value of human touch.

Turner PK.

Midwifery Today Int Midwife. 2001 Summer;(58):34-5. No abstract available.

PMID:
12154716
22.

Assessment of toxicity reduction in wastewater effluent flowing through a treatment wetland using Pimephales promelas, Ceriodaphnia dubia, and Vibrio fischeri.

Hemming JM, Turner PK, Brooks BW, Waller WT, La Point TW.

Arch Environ Contam Toxicol. 2002 Jan;42(1):9-16.

PMID:
11706362

Supplemental Content

Loading ...
Support Center